AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lisuride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ergot alkaloid derivatives | 1588 | 18016-80-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS).
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.25 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 14 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.73 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 13.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 49 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K21,MAPK7,SIK2,STK33,TEK | 15 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02CB02 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Prolactine inhibitors |
| ATC | N02CA07 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Ergot alkaloids |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D018491 | Dopamine Agonists |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:51065 | dopamine agonist |
| CHEBI has role | CHEBI:66956 | antidyskinesia agent |
Related Drugs by ATC class:
G02CB Prolactine inhibitors 5 drugs
N02CA Ergot alkaloids 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Amenorrhea | indication | 14302001 | DOID:13938 |
| Migraine | indication | 37796009 | DOID:6364 |
| Acromegaly | indication | 74107003 | DOID:2449 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.8 | acidic |
| pKa2 | 13.36 | acidic |
| pKa3 | 6.95 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2B | GPCR | ANTAGONIST | Ki | 8.49 | DRUG MATRIX | DRUG LABEL | |||
| Beta-2 adrenergic receptor | GPCR | Ki | 7.54 | DRUG MATRIX | |||||
| D(1A) dopamine receptor | GPCR | Ki | 7.11 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 9.30 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 9.94 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 9.40 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 9.06 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | AGONIST | Ki | 8.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 8.26 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.30 | IUPHAR | ||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 9.63 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 8.77 | CHEMBL | |||||
| D(1B) dopamine receptor | GPCR | AGONIST | Ki | 8.50 | IUPHAR | ||||
| Histamine H1 receptor | GPCR | Ki | 7.72 | DRUG MATRIX | |||||
| Histamine H2 receptor | GPCR | Ki | 5.99 | DRUG MATRIX | |||||
| Beta-1 adrenergic receptor | GPCR | Ki | 6.49 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 9 | IUPHAR | ||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 9.20 | DRUG MATRIX | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
| D(4) dopamine receptor | GPCR | AGONIST | Ki | 8.30 | IUPHAR | ||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 8.04 | DRUG MATRIX | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.78 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.70 | IUPHAR | ||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.17 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 8.34 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 7.64 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Kd | 9.52 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 9.33 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 9.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 8.30 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D01462 | KEGG_DRUG |
| 19875-60-6 | SECONDARY_CAS_RN |
| C0023863 | UMLSCUI |
| CHEBI:51164 | CHEBI |
| H8G | PDB_CHEM_ID |
| CHEMBL157138 | ChEMBL_ID |
| DB00589 | DRUGBANK_ID |
| D008090 | MESH_DESCRIPTOR_UI |
| 28864 | PUBCHEM_CID |
| 43 | IUPHAR_LIGAND_ID |
| 3065 | INN_ID |
| E0QN3D755O | UNII |
| 6446 | RXNORM |
| 003989 | NDDF |
| 003990 | NDDF |
| 323159002 | SNOMEDCT_US |
| 349894007 | SNOMEDCT_US |
| 395770007 | SNOMEDCT_US |
| E0QN3D755O | INXIGHT DRUGS |
Pharmaceutical products:
None